SPY
734.25
+0.17%
QQQ
651.16
+0.63%
BTC/USD
75,580.80
−0.51%
DIA
513.35
−0.18%
GLD
374.92
−0.15%
TLT
81.84
−0.11%
Try
Free
US
Sign in
Register
My Account
Benzinga
Premium Services
Services
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
Conmed Corp
CNMD
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$52.83
-0.83
-1.55%
Last update: Nov 5, 4:00 PM
Get Report
Overview
News
Earnings Forecast
Events
Price Targets
Financials
Sentiment
Ownership
Dividends
Compare
Options
Stock Report
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
Dividend:
The dividend Ex-Date is in 10 days
Conmed Financials
Conmed (CNMD) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Conmed Raises FY2026 Adj EPS Guidance from $4.48-$4.60 to $4.54-$4.61 vs $4.54 Est; Narrows FY2026 Sales Guidance from $1.358B-$1.373B to $1.360B-$1.366B vs $1.366B Est
Conmed (NYSE:CNMD) raises FY2026 Adj EPS guidance from $4.48-$4.60 to $4.54-$4.61 vs $4.54 analyst estimate. Narrows FY2026 sales outlook from $1.358 billion-$1.373 billion to $1.360 billion-$1.366 billion vs $1.366
Benzinga Newsdesk
PRO
Conmed Q3 Adj. EPS $1.04 Beats $1.00 Estimate, Sales $335.557M Miss $336.226M Estimate
Conmed (NYSE:CNMD) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $1.00 by 4 percent. This is a 3.7 percent decrease over earnings of $1.08 per share from the same period
Benzinga Newsdesk
PRO
Conmed Sees FY2026 Adj EPS $4.48-$4.60 vs $4.34 Est; Narrows FY2026 Sales Guidance from $1.350B-$1.375B to $1.358B-$1.373B vs $1.362B Est
Conmed (NYSE:CNMD) is looking for FY2026 Adj EPS of $4.48-$4.60 vs $4.34 analyst estimate. Narrows FY2026 sales outlook from $1.350 billion-$1.375 billion to $1.358 billion-$1.373 billion vs $1.362 billion estimate.
Benzinga Newsdesk
PRO
Conmed Q2 Adj. EPS $1.38 Beats $1.11 Estimate, Sales $343.488M Beat $337.564M Estimate
Benzinga Newsdesk
PRO
Conmed Raises FY2026 Sales Guidance from $1.345B-$1.375B to $1.350B-$1.375B vs $1.359B Est
Conmed (NYSE:CNMD) raises FY2026 sales outlook from $1.345 billion-$1.375 billion to $1.350 billion-$1.375 billion vs $1.359 billion estimate.
Benzinga Newsdesk
PRO
Conmed Q1 Adj. EPS $0.89 Beats $0.82 Estimate, Sales $317.046M Beat $310.507M Estimate
Conmed (NYSE:CNMD) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.82 by 8.54 percent. This is a 6.32 percent decrease over earnings of $0.95 per share from the same period
Benzinga Newsdesk
